Skip to content

Clinical Study on Noninvasive Acoustic Stimulation in The Treatment of Insomnia Comorbidized Depression

Clinical Study on Noninvasive Neuromodulation Technique of Acoustic Stimulation in The Treatment of Insomnia Comorbidized Depression

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500113736
Enrollment
Unknown
Registered
2025-12-02
Start date
2024-05-08
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression State

Interventions

Experimental Group:Noninvasive Neuromodulation Therapy of Acoustic Stimulation and Antidepressant Medicine Therapy
Control Group:Antidepressant Medicine Therapy

Sponsors

Sichuan Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
16 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.The age range is 16-80 years old; 2.Meet the diagnostic criteria of ICD-11 insomnia and depression, PSQI score is not less than 11 points and SDS score is not less than 53 points; 3.Junior high school education or higher level, with basic reading and writing skills. 4.With informed consent from the individual and legal guardian obtained.

Exclusion criteria

Exclusion criteria: 1. History of major systemic diseases (e.g., severe cardiac, cerebral, hepatic, or hematopoietic disorders) or other severe conditions affecting life expectancy; 2.Diagnosis of psychiatric disorders (e.g., schizophrenia, bipolar disorder, etc.); 3.Those with abnormal hearing or vision that has not been restored with physical assistance; 4.History of alcohol/substance abuse or psychoactive substance use; 5.Inability to complete psychological assessments; 6.Refusal to participate by the individual or legal guardian; 7.Patients with hyperacusis who have not recovered after desensitization therapy; 8.Current participation in another clinical trial.

Design outcomes

Primary

MeasureTime frame
Pittsburgh Sleep Quality Index (PSQI) Score;

Secondary

MeasureTime frame
Self-Rating Anxiety Scale (SAS) Score;Insomnia Severity Index (ISI) Scale Score;Melatonin Concentration;N2 Stage Sleep Duration;Total sleep time;Sleep Onset Latency;Neurotransmitter Concentration;Self-Rating Depression Scale (SDS) Score;Rapid eye movement sleep latency;REM Stage Sleep Duration;Oxidative Stress Biomarker Concentration;Hamilton Anxiety Rating Scale (HAMA) Score;Cytokine Concentration;Scores of HAMD;N3 Stage Sleep Duration;N1 Stage Sleep Duration;Blood fat;Fast blood -glucose;

Countries

China

Contacts

Public ContactLi Jing

Sichuan Provincial People's Hospital

lijingjingjing222@163.com+86 28 81020117

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026